Evidence map›Paper›PMID 36064324›Full record

ArticleBMC gastroenterology2022

Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites.

Omar Alshuwaykh, Amanda Cheung, Aparna Goel, Allison Kwong, Renumathy Dhanasekaran, T Tara Ghaziani, Aijaz Ahmed, Tami Daugherty, Deepti Dronamraju, Radhika Kumari and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Omar AlshuwaykhDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
Amanda CheungDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
Aparna GoelDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
Allison KwongDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
Renumathy DhanasekaranDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
T Tara GhazianiDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
Aijaz AhmedDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
Tami DaughertyDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
Deepti DronamrajuDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
Radhika KumariDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
Mindie NguyenDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
W Ray KimDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA.
Paul Yien KwoDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA. pkwo@stanford.edu.ORCID http://orcid.org/0000-0002-8234-4485
Stanford Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignancy-related ascites accounts for approximately 10% of causes of ascites. Our AIM was to characterize the ascites fluid and correlate clinical outcomes in those with extrahepatic malignancy and ascites.

methods241 subjects with extrahepatic solid tumors and ascites were reviewed from 1/1/2000 to 12/31/2019, 119 without liver metastasis and 122 with liver metastasis.

resultsAscites fluid consistent with peritoneal carcinomatosis (PC) was most common, 150/241 (62%), followed by fluid reflecting the presence of portal hypertension (PH), 69/241 (29%). 22/241 (9%) had low SAAG and low ascites fluid total protein, with evidence of PC on cytology and or imaging in 20/22. Lung cancer was the most common malignancy in subjects with ascites due to PC at 36/150 (24%), pancreatic cancer was the most common in subjects with ascites with features of PH at 16/69 (23%). Chemotherapy or immunotherapy alone was the most common management approach. Significantly higher 5-year, 3-year and 1-year mortality rate were noted in subjects with evidence of PC on cytology/imaging versus subjects with no evidence of PC, and in subjects with liver metastasis compared to subjects without liver metastasis. Subjects with pancreatic cancer and evidence of PC on cytology/imaging had higher 1 and 5-year mortality rates compared to subjects without PC.

conclusionsAscites in solid tumor malignancy is most commonly due to PC. We also observed ascites fluid with characteristics of PH in 29% of subjects. Higher mortality rates in subjects with peritoneal carcinomatosis and liver metastasis were noted. These findings may help inform prognosis and treatment strategies.

Indexed as

Hypertension, PortalLiver NeoplasmsPancreatic NeoplasmsPeritoneal NeoplasmsAscitesAscitic FluidHumansMalignant ascitesPeritoneal carcinomatosisPortal hypertensionSerum ascites albumin gradient

Identifiers

PMID36064324
PMCPMC9446745
OpenAlexW4294691602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.